Shares of Dendreon Corporation (NASDAQ: DNDN) rallied on Friday after analysts at Bernstein Research boosted its rating on the pharmaceutical company to “outperform” and raised its price target on stock by 43% to $10, citing upbeat outlook on company’s prostate cancer treatment. The 52-week trading of the stock is $5.73-$6.02.
Continue reading Major Movers on January 11; DNDN, BBY, KBR, INFY, ARQL, JCP, WFC